Latest Conference Articles

November 6th 2020, 11:14pm

PER® Chemotherapy Foundation Symposium (CFS)

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

November 6th 2020, 10:43pm

International Kidney Cancer Symposium

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

November 6th 2020, 8:16pm

International Kidney Cancer Symposium

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

November 6th 2020, 6:49pm

International Kidney Cancer Symposium

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.

November 6th 2020, 5:14pm

PER® Chemotherapy Foundation Symposium (CFS)

Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.

November 6th 2020, 3:44pm

PER® Chemotherapy Foundation Symposium (CFS)

Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.

November 6th 2020, 3:38pm

PER® Chemotherapy Foundation Symposium (CFS)

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.

November 5th 2020, 7:39pm

PER® Chemotherapy Foundation Symposium (CFS)

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

November 5th 2020, 7:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

November 5th 2020, 6:54pm

PER® Chemotherapy Foundation Symposium (CFS)

There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.

November 5th 2020, 4:23pm

PER® Chemotherapy Foundation Symposium (CFS)

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.

November 4th 2020, 8:10pm

PER® Chemotherapy Foundation Symposium (CFS)

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

November 4th 2020, 7:45pm

PER® Chemotherapy Foundation Symposium (CFS)

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

November 4th 2020, 4:08pm

PER® Chemotherapy Foundation Symposium (CFS)

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

October 29th 2020, 4:46pm

SMR Congress

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

October 29th 2020, 2:59pm

SMR Congress

The addition of anti–PD-1/PD-L1 to combination BRAF and MEK inhibition has been shown to improve progression-free survival and duration of response in patients with BRAF-mutated melanoma, suggesting potential to overcome resistance to targeted approaches.

October 28th 2020, 11:00pm

SMR Congress

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

October 28th 2020, 11:00pm

SMR Congress

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

October 3rd 2020, 9:32pm

NANETS Symposium

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

October 3rd 2020, 9:00pm

NANETS Symposium

The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.